1-5 of 5
Yifah Yaron
Close
Sort by
Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2023-182345
Published: 2023
Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan
Journal: Blood
Blood (2022) 140 (Supplement 1): 7284–7285.
https://doi.org/10.1182/blood-2022-159665
Published: 2022
Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Elliott Vichinsky, MD, Carolyn Hoppe, Jo Howard, Kenneth I. Ataga, Videlis Nduba, Amal El-Beshlawy, David L. Diuguid, Salam Al-Kindi, Clark Brown, Hoda Hassab, MD, Paul Telfer, Dimitris A. Tsitsikas, Selma Unal, Julie Kanter, MD, Miguel R. Abboud, Victor R. Gordeuk, MD, Joshua Lehrer-Graiwer, Claire Sherman, Margaret Tonda, PharmD, Allison Intondi, Yifah Yaron, Russell E. Ware, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 505.
https://doi.org/10.1182/blood-2018-99-118508
Published: 2018
Journal Articles

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

Carolyn C Hoppe, MD, Adlette C. Inati, MD, Clark Brown, MD PhD, Winfred Wang, MD, Victor R. Gordeuk, MD, Robert Liem, MD, Gerald Woods, MD, Connie M. Piccone, MD, Erica Fong, Ganesh Balaratnam, MD, Sandy Dixon, Margaret E Tonda, PharmD, Carla B Washington, PhD, Yifah Yaron, MD PhD, Josh Lehrer, MD MPhil, FACC
Journal: Blood
Blood (2017) 130 (Supplement 1): 689.
https://doi.org/10.1182/blood.V130.Suppl_1.689.689
Published: 2017
Journal Articles

Characterization of HOX Gene Expression During Myelopoiesis: Role of HOX A5 in Lineage Commitment and Maturation

John F. Fuller, Jeanne McAdara, Yifah Yaron, Mark Sakaguchi, John K. Fraser, Judith C. Gasson
Journal: Blood
Blood (1999) 93 (10): 3391–3400.
https://doi.org/10.1182/blood.V93.10.3391.410k26_3391_3400
Published: 1999